On Tuesday, International Business Machines Corp. (NYSE:IBM)’s shares inclined 0.21% to $165.68.
International Business Machines Corp (IBM) revealed new cloud services to assist businesses of any size quickly build, test and deploy applications to deliver more engaging customer experiences.
The new IBM Digital Experience on Cloud user experience platform provides companies with a fully managed cloud service for delivering compelling, socially aware, and omnichannel digital experiences to engage customers, partners and employees. Demand for mobile access from every device, integrated social capabilities, and the need to analyze data from the internet-of-things to quickly make decisions are prompting companies to look for faster ways to create better customer experiences.
New IBM Digital Experience on Cloud coupled with Portico software in the cloud allows Chief Marketing Officers (CMO), Chief Information Officers (CIO) and Chief Human Resources Officers (CHRO) to quickly pilot, configure and introduce new applications that meet evolving customer needs.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support.
Palatin Technologies, Inc. (NYSEMKT:PTN)’s shares dropped -0.87% to $1.14.
Palatin Technologies, Inc. (PTN) FDA Advisory Committee’s recommendation for the approval of flibanserin is an important step forward in women’s health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option.
HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, and cannot be accounted for by another medical physical or psychiatric condition, or a substance-like medication. It is estimated that one in 10 women may have the signs of HSDD at some point in their life, and as such HSDD represents a major opportunity to address a tremendous medical need with therapies like flibanserin and bremelanotide.
Palatin Technologies is excited to continue the development of bremelanotide, a first-in-class, as needed, melanocortin-4 receptor agonist being studied for the treatment of HSDD in pre-menopausal women. Bremelanotide has a novel mechanism that activates endogenous pathways in the brain involved in creating a sexual response. It is unique because bremelanotide is an as-needed (not chronic), centrally-mediated medication. Studies have shown that it starts working within 30 to 60 minutes of administration and remains effective for about eight hours, providing women with greater control and flexibility in their treatment.
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has accomplished Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs comprise Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has accomplished Phase I clinical trial for the treatment of cardiovascular and pulmonary indications, in addition to other melanocortin programs.
At the end of Tuesday’s trade, Xilinx, Inc. (NASDAQ:XLNX)‘s shares surged 0.26% to $46.45.
Xilinx, Inc. (XLNX) and Lattice Semiconductor Corp - are likely to benefit, analysts say.
With Altera becoming part of Intel, the San Jose-based company is likely to focus on the x86 microprocessors made by the world’s biggest chip company, rather than those made by companies such as ARM Holdings Plc.
Altera now provides chips for both x86 and ARM-based processors.
That gives Xilinx and Lattice the opportunity to take a bigger share of the ARM-based market - Xilinx at the high end and Lattice at the low end.
Lattice Chief Executive Darin Billerbeck told Reuters this week he predictable the Intel-Altera deal to enhance his company’s total addressable market by $300-$400 million.
Intel processors are geared to function with high-performance desktops and servers, and consume a lot of power. ARM-based processors are more power-efficient as they take less time to perform a function, making them suited for smartphones.
Intel has said that combining Altera’s chips with its own server processors, such as the x86, will let it offer twice the computing power.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Receptos Inc (NASDAQ:RCPT), ended its Tuesday’s trading session with 2.45% gain, and closed at $160.44.
Receptos Inc (RCPT) held its 2015 Annual Meeting of Stockholders. Three proposals were voted on at the meeting: (1) the election of each of William H. Rastetter, Ph.D., Richard A. Heyman, Ph.D., and Mary Szela as Class II directors to serve until the 2018 Annual Meeting of Stockholders;
(2) the ratification of the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015; and
(3) the approval of an amendment to the Company’s Employee Stock Purchase Plan, or ESPP, that modifies the evergreen provision to provide that the additional number of shares automatically added to the shares authorized for issuance under the ESPP on the first day of each fiscal year, commencing after the date of the ESPP amendment through January 1, 2023, shall be equal to the lesser of: (i) 1% of the outstanding shares on such date; (ii) 320,000 shares of common stock; or
(iii) such lesser amount as determined by the Board of Directors.
Only stockholders of record as of the close of business on April 2, 2015 were entitled to vote at the 2015 Annual Meeting. As of April 2, 2015, there were 31,548,710 shares of common stock of the Company outstanding and entitled to vote at the 2015 Annual Meeting. At the 2015 Annual Meeting, 27,280,747 shares of common stock of the Company were represented, in person or by proxy, constituting a quorum for the meeting.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product comprises ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
